Today, Liberum Capital Upgraded Astrazeneca PLC (AZN) to “Buy”

Today, Liberum Capital Upgraded Astrazeneca PLC (AZN) to “Buy”

Astrazeneca PLC (NYSE:AZN) was upgraded by Liberum Capital from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other analysts have also commented on the company. Leerink Swann reaffirmed a “market perform” rating on shares of Astrazeneca PLC in a research note on Thursday, November 10th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Beaufort Securities reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, November 11th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday, November 10th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company. Astrazeneca PLC currently has an average rating of “Buy” and a consensus price target of $37.61.

Astrazeneca PLC (NYSE:AZN) traded up 2.35% during mid-day trading on Friday, hitting $26.99. 4,096,609 shares of the stock traded hands. The firm’s 50-day moving average is $29.20 and its 200 day moving average is $30.75. The firm has a market cap of $68.28 billion, a P/E ratio of 27.70 and a beta of 0.83. Astrazeneca PLC has a 52-week low of $25.88 and a 52-week high of $35.04.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, November 10th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The company earned $5.70 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter last year, the firm posted $1.03 earnings per share. The firm’s revenue was down 2.6% on a year-over-year basis. Equities analysts predict that Astrazeneca PLC will post $3.02 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Veritable L.P. increased its position in shares of Astrazeneca PLC by 0.5% in the second quarter. Veritable L.P. now owns 9,972 shares of the company’s stock worth $301,000 after buying an additional 54 shares during the period. Budros Ruhlin & Roe Inc. increased its position in shares of Astrazeneca PLC by 0.4% in the third quarter. Budros Ruhlin & Roe Inc. now owns 16,724 shares of the company’s stock worth $550,000 after buying an additional 65 shares during the period. Fifth Third Bancorp increased its position in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the period. Logan Capital Management Inc. increased its position in shares of Astrazeneca PLC by 0.6% in the first quarter. Logan Capital Management Inc. now owns 19,698 shares of the company’s stock worth $554,000 after buying an additional 109 shares during the period. Finally, Independent Portfolio Consultants Inc. increased its position in shares of Astrazeneca PLC by 0.6% in the third quarter. Independent Portfolio Consultants Inc. now owns 22,720 shares of the company’s stock worth $738,000 after buying an additional 145 shares during the period. Institutional investors and hedge funds own 11.81% of the company’s stock.

Astrazeneca PLC Company Profile

Related posts

Leave a Comment